410076-95-8

Upstream product

• 410076-93-6 3-O-benzyl-1,2-di-O-acetyl-5-O-(methylsulfonyl)-4-C-(methylsulfonyloxymethyl)-α,β-L-threo-pentofuranose 
• 410076-92-5 3-O-benzyl-5-O-(methanesulfonyl)-4-C-[[(methanesulfonyl)oxy]methyl]-1,2-O-isopropylidene-β-L-threo-pentofuranose 
• 72261-44-0 1,2-O-isopropylidene-3-O-benzyl-4-C-(hydroxymethyl)-β-L-threo-pento-1,4-furanose 
• 673456-35-4 C₃₈H₄₃N₅O₇Si 
• 673456-36-5 [(3R,4R,5R)-5-(6-Amino-purin-9-yl)-3-benzyloxy-4-(tert-butyl-dimethyl-silanyloxy)-2-hydroxymethyl-tetrahydro-furan-2-yl]-methanol 
• 341536-45-6 9-[2-O-acetyl-5-O-benzoyl-4-C-[(benzoyloxy)methyl]-3-O-benzyl-α-L-threo-pentofuranosyl]-6-N-benzoyladenine 
• 673456-34-3 C₃₉H₃₃N₅O₈ 
• 4005-49-6 N-benzoyladenine 
• 673456-37-6 Methanesulfonic acid (3R,4R,5R)-5-(6-benzoylamino-purin-9-yl)-3-benzyloxy-4-(tert-butyl-dimethyl-silanyloxy)-2-methanesulfonyloxymethyl-tetrahydro-furan-2-ylmethyl ester 
• 410076-94-7 9-[2-O-acetyl-3-O-benzyl-5-O-(methanesulfonyl)-4-C-[[(methanesulfonyl)oxy]methyl]-α-L-threo-pentofuranosyl]-6-N-benzoyladenine 

Downstream Products

• 673456-39-8 (1S,3R,4R,7R)-7-benzyloxy-1-hydroxymethyl-3-(adenin-9-yl)-2,5-dioxabicyclo[2.2.1]heptane 
• 1067885-82-8 (1S,3R,4S,7R)-3-(6-N-benzoyladenin-9-yl)-1-(4,4′-dimethoxytrityloxymethyl)-7-hydroxy-2-oxa-5-azabicyclo[2.2.1]heptane 
• 1067885-81-7 (1S,3R,4S,7R)-3-(6-N-benzoyladenin-9-yl)-7-hydroxy-1-hydroxymethyl-2-oxa-5-azabicyclo[2.2.1]heptane 
• 1067885-80-6 (1S,3R,4S,7R)-3-(6-N-benzoyladenin-9-yl)-1-benzoyloxymethyl-7-hydroxy-5-trifluoroacetyl-2-oxa-5-azabicyclo[2.2.1]heptane 
• 1067885-78-2 (1S,3R,4S,7R)-3-(6-N-benzoyladenin-9-yl)-7-hydroxy-1-methanesulfonyloxymethyl-5-trifluoroacetyl-2-oxa-5-azabicyclo[2.2.1]heptane 
• 1067885-77-1 (1S,3R,4S,7R)-3-(6-N-benzoyladenin-9-yl)-7-benzyloxy-1-methanesulfonyloxymethyl-5-trifluoroacetyl-2-oxa-5-azabicyclo[2.2.1]heptane 
• 625111-41-3 9-[2-C-azido-3-O-benzyl-2-deoxy-4-C-methanesulfonyloxymethyl-5-O-methanesulfonyl-α-L-erythro-pentofuranosyl]-6-N-benzoyladenine 
• 1067885-87-3 (1S,3R,4S,7R)-3-(6-N-benzoyladenin-9-yl)-7-[2-cyanoethoxy-(diisopropylamino)phosphinoxy]-1-(4,4′-dimethoxytrityloxymethyl)-5-(pyren-1-yl)carbonyl-2-oxa-5-azabicyclo[2.2.1]heptane 
• 1067885-85-1 (1S,3R,4S,7R)-3-(6-N-benzoyladenin-9-yl)-7-[2-cyanoethoxy-(diisopropylamino)phosphinoxy]-1-(4,4′-dimethoxytrityloxymethyl)-5-(pyren-1-yl)methyl-2-oxa-5-azabicyclo[2.2.1]heptane 
• 1067885-86-2 (1S,3R,4S,7R)-3-(6-N-benzoyladenin-9-yl)-1-(4,4′-dimethoxytrityloxymethyl)-7-hydroxy-5-(pyren-1-yl)carbonyl-2-oxa-5-azabicyclo[2.2.1]heptane 
• 1067885-84-0 (1S,3R,4S,7R)-3-(6-N-benzoyladenin-9-yl)-1-(4,4′-dimethoxytrityloxymethyl)-7-hydroxy-5-(pyren-1-yl)methyl-2-oxa-5-azabicyclo[2.2.1]heptane 
• 410076-96-9 9-(2-O-acetyl-3-O-benzyl-5-O-(methanesulfonyl)-4-C-[[(methanesulfonyl)oxy]methyl]-α-L-erythro-pentofuranosyl)-6-N-benzoyladenine 
• 206055-79-0 (1S,3R,4S,7R)-7-[2-cyanoethoxy(diisopropylamino)phosphinoxy]-1-[[(4,4'-dimethoxytrityl)oxy]methyl]-3-(6-N-benzoyladenin-9-yl)-2,5-dioxabicyclo[2.2.1]heptane 
• 341536-51-4 (1S,3R,4S,7R)-1-[[(4,4'-dimethoxytrityl)oxy]methyl]-7-hydroxy-3-(6-N-benzoyladenin-9-yl)-2,5-dioxabicyclo[2.2.1]heptane 

Relevant academic research and scientific papers

Synthesis and characterization of oligodeoxyribonucleotides modified with 2′-amino-α-l-LNA adenine monomers: High-affinity targeting of single-stranded DNA

The development of conformationally restricted nucleotide building blocks continues to attract considerable interest because of their successful use within antisense, antigene, and other gene-targeting strategies. Locked nucleic acid (LNA) and its diaster

Synthesis of a base-protected xylo-LNA adenine nucleoside

Synthesis of (1S,3R,4R,7R)-7-hydroxy-1-hydroxymethyl-3-(6-N-benzoyl-adenin-9-yl)-2, 5-dioxabicyclo[2.2.1]heptane (2), a base-protected xylo-LNA adenine nucleoside, has been accomplished using a convergent synthetic strategy starting from 1,2-di-O-acetylfu

&α-L-ribo-Configured Locked Nucleic Acid (&α-L-LNA): Synthesis and Properties

The syntheses of monomeric nucleosides and 3'-O-phosphoramidite building blocks en route to α-L-ribo-configured locked nucleic acids (α-L-LNA), composed entirely of α-L-LNA monomers (α-L-ribo configuration) or of a mixture of α-L-LNA and DNA monomers (β-D